ROLE OF ANTIOXIDANT THERAPY IN PREVENTION OF LIPOPEROXIDATION AND PROCOAGULANT ACTIVITY OF PLATELETS IN SARS-COV-2 VIRAL INFECTIONS
Abstract
Based on a metanalysis of clinical observations in different countries with practical experience in the treatment of pneumonia complicated by the syndrome of multiple organ failure caused by the COVID-19 coronavirus, it is impossible to draw an unambiguous conclusion about the effectiveness of various therapies in patients. viruses modify the apparatus of biosynthesis of cells in the body as a whole. Therefore, finding drugs that have an exceptional effect on viruses without infecting the body is a difficult task. Various antiviral drugs (ribaverin, interferons and glucocorticosteroids, antiparasitic, antimalarials (Chloroquine, Hydroxychloroquine) are effective at certain stages of the infectious process, however, they are toxic and therapy with these drugs has risks of developing severe cytopenia, hepatotoxicity, neuropsychiatric disorders and severe ischemia Interleukin antagonists (Tocilizumab, Anakindra, Levilimab) are effective in severe cases with an increase in IL-6, as they limit the cascade of activation of cells of the immune system, reduce the effect of "cytokine storm" in the formation of acute respiratory distress syndrome and endothelial dysfunction of the pulmonary vessels.
Discussion. In an experimental study R.G. Alborov, in the framework of the dissertation for the degree of candidate of medical sciences (2001), in which nonlinear white rats were used, it was demonstrated that: activators of lipid peroxidation (LPO), different in nature and biological activity, inhibition of the transformation of arachidonic acid in platelets reduces, along with proaggregant activity, the intensity of LPO processes in them. Based on the experimental data obtained, it can be considered appropriate to study the effect of antioxidants as agents that enhance the effects of antiplatelet inhibitors of the transformation of arachidonate and platelets. It can be expected that antioxidants, by reducing the procoagulant activity of platelets, due to inhibition of LPO, can enhance the effect of antiplatelet agents.
Findings. 1. The effectiveness of antioxidant therapy for infection with SAPS-COV-2 viruses, including COVID-19, is beyond doubt. It is important that antioxidant therapy was prescribed before the development of lipid peroxidation and "cytokine storm" and an increase in the procoagulant activity of platelets, that is, at the initial stage of infection.
- Antioxidant therapy presupposes adequate dosages according to the type of "saturating phase of treatment" with subsequent transfer to maintenance doses.
Currently, no drugs have been found that have an exceptional effect on viruses without affecting the body. Antioxidants are protective at the cellular level. In addition, they practically do not cause side effects. It is advisable to prescribe antioxidant drugs in large doses in the complex therapy of viral infections.
References
2. Kharkevich D.A. Uch. on pharmacology - M .: GEOTAR-Media. 2010.S. 628.
3.Byshevsky A.Sh., Umutbaeva M.K., Alborov R.G. Connection of hemostasis with lipid peroxidation / M. "Medical book", 2003. P.4-7.
4.Kartysheva K.Yu. / Antiviral drugs that suppress the activity of COVID-19. What is the effectiveness of their application? / Topical issues of medicine. Collection of articles of the II International Scientific and Practical Conference. 2020, p. 110-114.
5. Ministry of Health of the Russian Federation. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Temporary guidelines (version from 08/04/2020). M .: MZRF S. 122.
6. Gao J., Tian Z., Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci. Trends., 2020, vol. 14, no. 1, pp. 72-73.
7.Chiappelli F., Khakshooy A., Greenberg G. CoViD-19 immunopathology and immunotherapy. Bioinformation, 2020, vol. 16, no. 3, pp. 219-222. doi: 10.6026 / 97320630016219 17.
8.Gamino-Arroyo A.E., Guerrero M.L., McCarthy S., Ramírez-Venegas A., Llamosas-Gallardo B., Galindo-Fraga A., Moreno-Espinosa S., RoldánAragon Y., Araujo-Melendez J., Hunsberger S., IbarraGonzalez V., Martínez-Lopez J., GarciaAndrade L.A., Kapushoc H., Holley H.P., Smolskis M.C., RuizPalacios G.M., Beigel J.H., Mexico Emerging Infectious Diseases Clinical Research Network (LaRed). Efficacy and safety of Nitazoxanide in addition to standard of care for the treatment of severe acute respiratory illness. Clin. Infect. Dis., 2019, vol. 69, no. 11, pp. 1903-1911.
9.Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res., 2020, vol. 30, no. 3, pp. 269-271.
10. Wagstaff K.M., Sivakumaran H., Heaton S.M., Harrich D., Jans D.A. Ivermectin is a specific inhibitor of importin α / β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem. J., 2012, vol. 443, no. 3, pp. 851-856. doi: 10.1042 / BJ20120150
11. National Health Commission (NHC) of the People's Republic of China. The diagnosis and treatment guide of COVID-19 pneumonia caused by new coronavirus infection. 7th Edition (3 March,2020). URL: http://www.gov.cn/zhengce/zhengceku/2020-03/04/ content_5486705.htm (10.12.2020)
12. Cellina M., Orsi M., Bombaci F., Sala M., Marino P., Oliva G. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with Tocilizumab. Diagn. Interv. Imaging., 2020: S2211- 5684 (20) 30087-5. https://doi.org/10.1016 / j.diii.2020.03.010
13. Alborov R.G. The effect of inhibitors of the conversion of arachidonic acid on hemostasis depending on the intensity of lipid peroxidation in platelets. / Abstract of the dissertation of the candidate of medical sciences. Tyumen. 2001.
14. Volkov A.I. Hemocoagulation and lipid peroxidation in thyrotoxicosis / Scientific Bulletin of the TSMA. - 1999.3-4. 72-73.
15. Volkov A.I., Gorodnicheva I.E. Hemostasis and lipid peroxidation in hypothyroid state / Scientific Bulletin of the TSMA (ISBN No. 5-88131-099-3). 2001.9 (1). S. 136-145.
16. Alborov R.G. The role of blood cells in the relationship between thrombin tolerance, the content of thrombin-fibrinogen interaction products in the bloodstream and lipid peroxidation / Abstract of the dissertation of the doctor med. sciences. 2006.
17. Broder A.I. Effects of inhibitors of the transformation of arachidonic acid in the modification of lipid peroxidation / Scientific Bulletin of the TSMA (ISBN No. 5-88131-099-3).2001.6.S. 136-140.
18. Byshevsky A.Sh., Galyan S.L., Alborov R.G. et al. Influence of cyclooxygenase inhibitors on the level of markers of intravascular blood coagulation / Scientific Bulletin of the Tyumen Medical Academy. Special issue Bioantioxidants. 2003.1.P.86.
19. Byshevsky A.Sh., Galyan S.L., Alborov R.G. and other Hemostatic shifts in aorto-femoral and femoral-popliteal bypass grafting in patients with obliterating atherosclerosis of the vessels of the lower extremities, their correction by selmevitis / Surgery. 2004.10.S. 38-41.
20. Byshevsky A.Sh., Umutbaeva M.K., Alborov R.G. Antioxidants in the correction of blood coagulation shifts / Moscow:Medical book. 2004.S. 79.
CC BY-ND
A work licensed in this way allows the following:
1. The freedom to use and perform the work: The licensee must be allowed to make any use, private or public, of the work.
2. The freedom to study the work and apply the information: The licensee must be allowed to examine the work and to use the knowledge gained from the work in any way. The license may not, for example, restrict "reverse engineering."
2. The freedom to redistribute copies: Copies may be sold, swapped or given away for free, in the same form as the original.
